Moderna projected substantial revenue between $8 billion and $15 billion from its portfolio of Covid, RSV, flu, and other respiratory vaccines by 2027, accompanied by an operating profit ranging from $4 billion to $9 billion.
The biotech firm disclosed plans to bolster this forecast with additional research investments totaling $6 billion to $8 billion over the coming years.
This announcement preceded Moderna’s Vaccine Day, an annual event where the company updates investors and analysts on its vaccine portfolio, crucial as it navigates a post-pandemic surge.
Earlier projections for 2023 anticipate $5 billion in sales from its mRNA Covid vaccine, significantly down from the $18 billion recorded in the previous year, reflecting the evolving market dynamics post-pandemic.
Despite setbacks, including a disappointing late-stage trial for its flu vaccine, Moderna emphasized its pipeline expansion, aiming to launch six major vaccine products in the near future.
Analysts, however, anticipate debates among investors regarding the 2027 guidance, given uncertainties about the trajectory of seasonal viruses like Covid.
Among Moderna’s key products driving its 2027 outlook is its RSV vaccine, positioned alongside other respiratory products.
The company expects to file for full FDA approval for adults aged 60 and older this quarter, with potential regulatory decisions expected by late 2023 or early 2024.
Moderna’s RSV vaccine, which received Breakthrough Therapy Designation, demonstrated robust effectiveness in clinical trials without safety concerns such as Guillain-Barre Syndrome, a noted issue with competitor vaccines.
Moderna’s efforts extend to pediatric populations, with ongoing studies for its RSV vaccine in children, including a recent pediatric trial for ages five months to two years.
This study also explores a combination vaccine targeting both RSV and human metapneumovirus, underscoring Moderna’s comprehensive approach to respiratory health solutions.
